Teladoc Health (NYSE:TDOC) Shares Break Above Two Hundred Day Moving Average - Here's What Happened

Key Points

• Teladoc shares broke above their 200-day moving average, reaching $6.92 and last trading near $6.87 on heavy volume.
• The company’s third-quarter results beat expectations, with a narrower-than-expected loss of $0.15 per share and revenue of $605.1 million versus estimates of about $588 million.
• Despite the earnings beat, revenue fell 3.4% year over year and Teladoc remained unprofitable; analysts maintain a consensus “Hold” rating with an average price target of $7.54.

Teladoc Health, Inc. (NYSE:TDOC - Get Free Report) crossed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $6.46 and traded as high as $6.92. Teladoc Health shares last traded at $6.8720, with a volume of 8,586,863 shares.

More Teladoc Health News

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Teladoc reported a third-quarter loss of $0.15 per share, narrower than the $0.22–$0.23 loss analysts expected and improved from a $0.21 loss a year earlier. Teladoc Reports Q3 Loss, Beats Revenue Estimates
• Positive Sentiment: Revenue totaled $605.1 million, surpassing the approximately $588 million consensus estimate. The earnings and revenue beats likely supported the stock’s upward move. Teladoc Health Reports Third Quarter 2026 Results
• Neutral Sentiment: Management issued fourth-quarter revenue guidance of approximately $569 million to $615 million, implying a midpoint near $592 million. This is close to expectations but indicates limited near-term growth momentum. Teladoc Fourth-Quarter Revenue Guidance
• Negative Sentiment: Third-quarter revenue declined roughly 3% year over year, highlighting continued pressure on the virtual-care business. Teladoc also remained unprofitable, reporting a $26.9 million net loss, a negative net margin, and negative return on equity. Teladoc Health Reports Third Quarter 2026 Results

Wall Street Analysts Forecast Growth

TDOC has been the topic of several recent analyst reports. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Teladoc Health in a research note on Wednesday, August 19th. Canaccord Genuity Group cut their price objective on Teladoc Health from $11.00 to $10.00 and set a "buy" rating for the company in a research report on Thursday, July 30th. Citigroup cut their price objective on Teladoc Health from $11.00 to $7.50 and set a "neutral" rating for the company in a research report on Monday, August 3rd. Finally, Bank of America boosted their price objective on shares of Teladoc Health from $9.00 to $10.50 and gave the company a "buy" rating in a report on Tuesday, July 7th. Five analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Teladoc Health presently has a consensus rating of "Hold" and an average price target of $7.54.

Teladoc Health Price Performance

The stock has a market cap of $1.25 billion, a PE ratio of -6.94 and a beta of 2.14. The business has a fifty day moving average of $6.15 and a 200 day moving average of $6.46.

Teladoc Health (NYSE:TDOC - Get Free Report) last issued its quarterly earnings data on Wednesday, October 28th. The health services provider reported ($0.15) earnings per share for the quarter, beating analysts' consensus estimates of ($0.22) by $0.07. The firm had revenue of $605.10 million during the quarter, compared to analyst estimates of $588.14 million. Teladoc Health had a negative return on equity of 12.15% and a negative net margin of 7.13%. Teladoc Health's quarterly revenue was down 3.4% on a year-over-year basis. During the same quarter last year, the firm earned ($0.28) EPS. On average, equities research analysts expect that Teladoc Health, Inc. will post -0.92 EPS for the current year.

Insider Activity

In other Teladoc Health news, CEO Charles III sold 17,805 shares of the firm's stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $6.10, for a total value of $108,610.50. Following the sale, the chief executive officer owned 465,535 shares of the company's stock, valued at $2,839,763.50. This trade represents a 3.68% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 0.70% of the company's stock.

Institutional Investors Weigh In On Teladoc Health

Institutional investors have recently added to or reduced their stakes in the stock. VIRGINIA RETIREMENT SYSTEMS ET Al boosted its stake in Teladoc Health by 9.5% in the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 186,825 shares of the health services provider's stock worth $1,084,000 after purchasing an additional 16,200 shares during the period. Partners Wealth Management LLC bought a new stake in shares of Teladoc Health in the 3rd quarter worth approximately $58,000. Oppenheimer & Co. Inc. raised its stake in Teladoc Health by 11.5% in the third quarter. Oppenheimer & Co. Inc. now owns 206,625 shares of the health services provider's stock worth $1,198,000 after buying an additional 21,334 shares in the last quarter. Sterling Capital Management LLC raised its holdings in Teladoc Health by 26.8% in the third quarter. Sterling Capital Management LLC now owns 49,909 shares of the health services provider's stock worth $289,000 after purchasing an additional 10,545 shares in the last quarter. Finally, SBI Securities Co. Ltd. lifted its holdings in shares of Teladoc Health by 37.2% during the third quarter. SBI Securities Co. Ltd. now owns 25,524 shares of the health services provider's stock valued at $148,000 after purchasing an additional 6,925 shares during the last quarter. 76.82% of the stock is owned by institutional investors and hedge funds.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services and technology designed to connect patients with medical professionals remotely. Through its digital platforms, the company supports a range of healthcare needs, including general medical consultations, mental health services, specialty care, and ongoing management of chronic conditions.

Its offerings include telehealth visits with physicians and other licensed providers, behavioral health services through BetterHelp, and chronic care programs that use digital tools and clinical support to help people manage conditions such as diabetes and hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.